Blog

Our Latest Blog Posts
  • BlueSky Immunotherapies Reaches Milestone with delNS Viral Vector for OPSCC Treatment 28
    Feb

    BlueSky Immunotherapies Reaches Milestone with delNS Viral Vector for OPSCC Treatment

    [vc_row][vc_column][vc_column_text]   BlueSky Immunotherapies Reaches Milestone with delNS Viral Vector for OPSCC Treatment Vienna, March 1st - Innovative Approach Shows Promise in Neoadjuvant Setting Vienna,…

    operator no responses
  • BlueSky Immunotherapies Commences Phase 1 Trial for Oropharyngeal Cancer Treatment 07
    Mar

    BlueSky Immunotherapies Commences Phase 1 Trial for Oropharyngeal Cancer Treatment

      BlueSky Immunotherapies Commences Phase 1 Trial for Oropharyngeal Cancer Treatment Vienna, March 7th - BlueSky Immunotherapies, a clinical stage biotech company in the field…

    operator no responses
  • Landmark in HPV Treatment: Excellent Safety and Substantial Efficacy of Viral Vector delNS/E6E7 in Phase 1 Trial 17
    Oct

    Landmark in HPV Treatment: Excellent Safety and Substantial Efficacy of Viral Vector delNS/E6E7 in Phase 1 Trial

    [vc_row][vc_column][laboratory_headings headings_title="Successful Phase 1 Trial Demonstrates Excellent Safety and Substantial Efficacy of Viral Vector delNS/E6E7 in Patients Infected with HPV16 and Cervical Lesions" headings_title_tag="h1" headings_subtitle=""…

    Norina Kruckenfellner no responses
  • BlueSky’s delNS technology makes tumours vulnerable to the immune system 09
    Dec

    BlueSky’s delNS technology makes tumours vulnerable to the immune system

    [vc_row][vc_column width="1/12"][/vc_column][vc_column width="10/12"][laboratory_headings headings_title="BlueSky’s delNS technology makes tumours vulnerable to the immune system" headings_subtitle="" headings_layout="t-only" laboratory_heading_font_weight="400" laboratory_heading_color="#312783" laboratory_sub_heading_font_weight="400"][vc_separator color="custom" border_width="4" el_width="10" accent_color="#312783"][vc_single_image image="3449" img_size="full" alignment="center"…

    operator no responses
  • Equine sarcoids: visible sucess with delNS-based immunotherapy 10
    Dec

    Equine sarcoids: visible sucess with delNS-based immunotherapy

    [vc_row][vc_column width="1/12"][/vc_column][vc_column width="10/12"][laboratory_headings headings_title="Sarcoids in horses: Next milestone in cancer therapy" headings_subtitle="" headings_layout="t-only" laboratory_heading_font_weight="400" laboratory_heading_color="#312783" laboratory_sub_heading_font_weight="400"][vc_separator color="custom" border_width="4" el_width="10" accent_color="#312783"][vc_single_image image="3354" img_size="full" alignment="center" style="vc_box_outline" border_color="black"…

    operator no responses
  • Patent protection for innovative technology-platform 09
    Mar

    Patent protection for innovative technology-platform

    [vc_row][vc_column width="1/12"][/vc_column][vc_column width="10/12"][laboratory_headings headings_title="Patent protection for innovative technology-platform" headings_subtitle="" headings_layout="t-only" laboratory_heading_font_weight="400" laboratory_heading_color="#312783" laboratory_sub_heading_font_weight="400"][vc_separator color="custom" border_width="4" el_width="10" accent_color="#312783"][vc_single_image image="2672" img_size="full" alignment="center" style="vc_box_outline" border_color="black" css_animation="none"][vc_column_text] BlueSky Immunotherapies…

    operator no responses